InvestorsHub Logo
Followers 163
Posts 12871
Boards Moderated 1
Alias Born 01/26/2016

Re: threefoot post# 64554

Wednesday, 06/15/2016 5:02:11 PM

Wednesday, June 15, 2016 5:02:11 PM

Post# of 698583
threefoot,

L is the closest to "being ready" for commercialization as far as we know. Big pharma wants quick turn around if possible and if UCLA's biomarker analysis can be approved for patient selection and a trial endpoint can be reduced to just immune response then you have a very quick turnaround with L. Much more is unproven and relatively unknown about Direct which is why the SAB is going to be helpful at putting the best minds together to work on proper anticipation of MO and, therefore, trial design. Best wishes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News